Effect of Aliskiren and Hydrochlorothiazide on Kidney Oxygenation in Patients With Hypertension

• Status: Completed
• Trial end date: 2014-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this project is to evaluate the chronic effect (8 weeks) of RASILEZ 300mg (aliskiren) on renal tissue oxygenation in patients with stage 1-2 hypertension, and to compare the chronic effect (8 weeks) of RASILEZ 300mg (aliskiren) on renal tissue oxygenation in patients with stage 1-2 hypertension with these effects with those of ESIDREX 25mg (hydrochlorothiazide).

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Centre Hospitalier Universitaire Vaudois
• Treatments: Hydrochlorothiazide

Criteria

Inclusion Criteria:

• Tolerance to study drugs

• Age > 18 years

• Arteria hypertension stage 1-2 (blood pressure: 140/90 and 180/110 mm Hg)

• Normal renal function

• Availability to give informed consent

Exclusion Criteria:

• Intolerance to study drugs

• Renal artery stenosis

• Hyperkalaemia > 5.0 mmol/l

• Contra-indications to the use of PAH, inulin or Lithium

• Asthma

• Pychiatric illness

• No estimated easy vascular venous access for placement of two peripherical venous catheters in forearms

• Contra-indication to MRI-imaging: Claustrophobia or Pacemaker or other implanted metal device